Shares of healthcare giant Johnson & Johnson saw a modest increase on Wednesday. This followed an upgrade by Leerink Partners, which raised its rating on the stock to "Outperform" and set a new 12-month price target of $265. The firm cited a significantly accelerated growth outlook for the company.
Four Blockbuster Drugs Drive Growth Leerink analysts stated that Johnson & Johnson is entering a period of stronger revenue expansion, with the core driver being four key products. The firm projects that Johnson & Johnson's compound annual growth rate for revenue from 2026 to 2031 will reach 7.2%, surpassing the general consensus on Wall Street.
The analysts specifically highlighted one oral therapy, describing it as "one of the most important products in the company's history," with projected sales potentially reaching $10.5 billion by 2032. Two other cancer therapies were also identified as significant growth engines.
Q1 Earnings Beat Expectations, Full-Year Guidance Raised This rating upgrade comes after Johnson & Johnson reported better-than-expected first-quarter results. Revenue reached $24.1 billion, a year-over-year increase of 9.9%, exceeding market expectations. Adjusted earnings per share were $2.70, also above forecasts.
The Innovative Medicine segment performed particularly well, with sales of $15.43 billion, marking an 11.2% increase from the previous year. Based on this strong start, the company raised its full-year revenue guidance for 2026.
Price Target Implies Upside Potential The $265 price target implies an approximate 18% upside from the stock's recent closing price. Despite the optimistic outlook, analysts also noted associated risks. These include potential setbacks in clinical trials, new drug launches underperforming expectations, legal exposures, and drug pricing pressures.
Comments